SCHEMBL9984369

SCHEMBL9984369

CC(C)(C)OC(=O)C1CNCCN1c1ccc(Nc2nc(Cl)ccc2[N+](=O)[O-])cc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 1/20 0.35
MAPT P10636 6/20 0.33
SYK P43405 2/20 0.33
GAA P10253 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
P2RX3 P56373 2/20 0.32
ROCK2 O75116 1/20 0.32
TDP1 Q9NUW8 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
HTT P42858 1/20 0.32
POLB P06746 1/20 0.32
PHGDH O43175 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
TACR1 P25103 1/20 0.32
GPR174 Q9BXC1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9984378 0.81 SYK (0.37) FGFR4MAPTSYKL3MBTL1HTT
SCHEMBL9983804 0.79 SYK (0.41) FGFR4MAPTSYKMAPK1L3MBTL1
SCHEMBL9983692 0.78 MAPT (0.44) MAPTKMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL9984259 0.75 ALDH1A1 (0.50) FGFR4MAPTGAAMEN1KMT2A
SCHEMBL9984065 0.74 TACR1 (0.38) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL9985257 0.74 MAPT (0.48) FGFR4MAPTMEN1KMT2AALDH1A1
SCHEMBL9987980 0.74 TDP1 (0.49) MAPTGAAMEN1KMT2ATDP1
SCHEMBL9985154 0.74 MAPT (0.45) FGFR4MAPTLMNAPOLBGPR174
SCHEMBL9985521 0.73 MAPT (0.57) MAPTSYKMEN1KMT2AALDH1A1
SCHEMBL16026451 0.72 GFER (0.47) MAPTGAAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME DONG WHA PHARM. CO., LTD. (KR) 2011-12-15 US disclosed
EP-2394993-A2 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Dong Wha Pharm. Co., Ltd. (KR) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME NOS3, PTMS, NOS2 FGFR4 1689/4885MAPT 4055/4885SYK 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.